查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790217

美國動物感染疾病物市場規模、佔有率和趨勢分析報告：按動物、產品、給藥途徑、類型、分銷管道和細分市場預測，2025 年至 2033 年

U.S. Veterinary Anti-infectives Market Size, Share & Trends Analysis Report By Animal, By Product, By Route Of Administration, By Type, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國動物感染疾病市場概況

美國獸用感染疾病物市場規模預計在 2024 年為 22.3 億美元，預計到 2033 年將達到 35.5 億美元，2025 年至 2033 年的複合年成長率為 5.4%。預計推動市場發展的關鍵因素包括感染疾病的增加、研發舉措的增加、推動謹慎使用抗生素、開發新型治療方法以及擴大人工智慧 (AI) 的應用。

由於人們對通用動物和牲畜的抗生素抗藥性 (AMR) 日益擔憂，美國獸用感染疾病市場正在經歷重大變革時期。 《新聞醫學》雜誌 2025 年 1 月的一項研究強調了家犬如何攜帶和傳播抗生素抗藥性沙門氏菌，從而增加了人畜共患感染疾病的風險。這提高了獸醫和飼主的認知，推動了對伴侶動物領域更有針對性和更安全的抗感染疾病解決方案的需求。獸醫實踐對頻譜抗生素的濫用越來越謹慎，促使人們對窄頻譜藥物、抗藥性緩解療法，甚至益生菌等預防性護理選擇產生了興趣。這種趨勢也刺激了獸醫診斷的發展，特別是藥敏測試，它有助於制定負責任的治療決策。

減少對抗生素依賴的技術創新正在進一步塑造畜牧業市場。賓州州立大學 2024 年 12 月的一項研究揭示了一種使用噬菌體代替抗生素治療乳牛乳房炎的有前景的新治療方法。這項開創性的研究凸顯了替代抗生素療法的市場不斷擴大，包括噬菌體療法、免疫調節劑、胜肽和其他生技藥品。美國食品藥物管理局和美國農業部對食用動物常規使用抗生素施加監管壓力，這增加了此類替代抗生素的採用，尤其是在乳品加工業和牛肉生產商中。這些相關人員現在要求有效的治療方法符合抗菌管理指南，同時保持牛健康和生產力，從而導致獸用感染疾病的範圍超越傳統抗生素。

同時，美國獸醫協會 (AVMA) 強調獸醫與飼主就負責任的抗生素使用進行溝通的重要性。這種以管理主導的方法正在重塑美國獸醫實踐的配藥行為。隨著獸醫優先考慮診斷驅動的治療並減少經驗性抗生素使用，對診斷、藥敏試驗和更複雜的抗感染療法的需求正在成長。製藥公司正在透過開發符合管理原則的精準醫療和教育資源來應對這一變化。這種轉變確保了更好的健康結果，並推動了市場對獸用感染疾病物創新的持續需求。

摘要：美國市場受三大驅動力驅動：伴侶動物抗菌藥物抗藥性威脅的發現、牲畜疾病非抗生素療法的出現以及獸醫管理文化的日益發展。這些因素正推動企業實現產品系列多元化，投資研發更安全的替代品，並開發支持負責任抗生素使用的工具。因此，市場正迅速朝精準化、永續性和創新性方向發展，共同對抗抗菌藥物抗藥性。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國動物感染疾病物市場趨勢與展望

  • 市場體系展望
    • 母市場
    • 子公司市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 美國動物感染疾病物市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析
    • 主要國家的法規結構
    • 按主要國家和物種分類的動物族群估計數（2021-2023 年）
    • 重大感染疾病（主要種類）流行情形（2024年）
    • COVID-19影響分析

第4章美國動物感染疾病物市場：依種類、估計和趨勢分析

  • 細分儀表板
  • 美國動物感染疾病物市場：動物變異分析
  • 美國動物感染疾病物市場規模及趨勢分析（依動物種類，2021-2033）
  • 家畜
    • 家禽
    • 豬
    • 牛
    • 綿羊和山羊
    • 魚
    • 其他
  • 伴侶動物
    • 狗
    • 貓
    • 其他

第5章美國動物感染疾病物市場：產品、估計與趨勢分析

  • 細分儀表板
  • 美國動物感染疾病物市場：產品差異分析
  • 美國動物感染疾病物市場規模及趨勢分析（依產品，2021-2033）
  • 抗菌劑
    • 頭孢菌素類
    • 四環黴素
    • 青黴素
    • 大環內酯類
    • 其他（對苯二酚、磺胺類藥物、多粘菌素）
  • 抗真菌藥物
  • 抗病毒藥物
  • 其他

第6章：美國動物感染疾病物市場依給藥途徑、估計及趨勢分析

  • 細分儀表板
  • 美國動物感染疾病物市場：給藥途徑變化分析
  • 美國動物感染疾病物市場規模及趨勢分析（依給藥途徑，2021-2033）
    • 口服
    • 注射
    • 其他

第7章：美國動物感染疾病物市場類型、估計與趨勢分析

  • 細分儀表板
  • 美國動物感染疾病物市場：按類型變化分析
  • 美國動物感染疾病物市場規模及趨勢分析（2021-2033）
    • 非處方藥
    • 處方箋

第8章：動物感染疾病物市場：按分銷管道進行的估計和趨勢分析

  • 細分儀表板
  • 美國動物感染疾病物市場：通路波動分析
  • 美國動物感染疾病物市場規模及通路趨勢分析（2021-2033）
    • 醫院/診所藥房
    • 零售藥局
    • 電子商務

第9章 競爭態勢

  • 市場參與企業分類
  • 企業市場分析/堆圖分析
  • 公司簡介
    • Zoetis
    • Boehringer Ingelheim
    • Merck & Co. Inc.
    • Dechra Pharmaceuticals Plc.
    • Elanco Animal Health
    • Ceva Sante Animale
    • Virbac
    • Biogenesis Bago
    • Vetoquinol
    • Calier
    • Norbrook Laboratories
  • 戰略地圖
    • 合併與收購
    • 夥伴關係和合作
    • 擴張
    • 產品發布
    • 產品核可
    • 其他
  • 主要企業名單
    • 製造商列表
    • 經銷商名單
Product Code: GVR-4-68040-656-7

U.S. Veterinary Anti-infectives Market Summary

The U.S. veterinary anti-infectives market was estimated at USD 2.23 billion in 2024 and is projected to reach USD 3.55 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. Key factors expected to drive the market include the rise in animal infectious diseases, increasing R&D initiatives, a boost to prudent antibiotic use, development of novel treatments, and growing applications of Artificial Intelligence (AI).

The veterinary anti-infectives market in the U.S. is undergoing a significant transformation, driven by rising concerns over antimicrobial resistance (AMR) in companion animals and livestock. A January 2025 study highlighted in News-Medical underscores how household dogs can harbor and transmit antibiotic-resistant Salmonella, elevating the risk of zoonotic infections. This has raised awareness among veterinarians and pet owners, leading to a growing demand for more targeted and safer anti-infective solutions in the companion animal segment. Veterinary practices are increasingly cautious about the indiscriminate use of broad-spectrum antibiotics, prompting interest in narrow-spectrum drugs, resistance-mitigating therapies, and even preventive care options like probiotics. This trend also fuels the growth of veterinary diagnostics, especially for susceptibility testing that helps guide treatment decisions responsibly.

Innovations to reduce antibiotic reliance further shape the market in the livestock sector. A Penn State study from December 2024 revealed a promising new treatment for mastitis in dairy cows using bacteriophages instead of antibiotics. This breakthrough highlights the expanding market for antibiotic alternatives, including phage therapies, immunomodulators, peptides, and other biologics. Regulatory pressure from the FDA and USDA to curb routine antibiotic use in food-producing animals has increased the adoption of such alternatives, especially among dairy and beef producers. These stakeholders are now seeking effective treatments that comply with antimicrobial stewardship guidelines while maintaining herd health and productivity, thus broadening the veterinary anti-infectives landscape beyond conventional antibiotics.

Meanwhile, the American Veterinary Medical Association (AVMA) has emphasized the importance of communication between veterinarians and animal owners around responsible antibiotic use. This stewardship-led approach is reshaping prescribing behavior across U.S. veterinary practices. As veterinarians prioritize diagnosis-driven treatments and reduce empirical antibiotic use, there is an increasing demand for diagnostics, sensitivity testing, and more refined anti-infective therapies. Pharmaceutical companies are responding by developing precision drugs and educational resources that align with stewardship principles. This shift ensures better health outcomes and drives sustained market demand for innovation in veterinary anti-infectives.

In summary, the U.S. market is propelled by three major forces: the detection of AMR threats in pets, the emergence of non-antibiotic treatments for livestock diseases, and a growing culture of veterinary stewardship. These factors drive market players to diversify product portfolios, invest in R&D for safer alternatives, and develop tools supporting responsible antibiotic use. The result is a market rapidly evolving toward precision, sustainability, and innovation in the fight against antimicrobial resistance.

U.S. Veterinary Anti-infectives Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary anti-infectives market report based on animal, product, route of administration, type, and distribution channel.

  • Animal Outlook (Revenue, USD Million, 2021 - 2033)
  • Livestock Animal
    • Poultry
    • Swine
    • Cattle
    • Sheep & Goats
    • Fish
    • Others
  • Companion Animal
    • Dogs
    • Cats
    • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Antimicrobial
    • Tetracyclines
    • Penicillin
    • Cephalosporins
    • Macrolides
    • Quinolones
    • Others
  • Antifungals
  • Antivirals
  • Antiparasitic
  • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
  • Topical
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • Prescription
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital/ Clinic Pharmacy
  • Retail Pharmacies
  • E-commerce

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Country Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Anti-infectives Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rise in Infectious Diseases Among Animals
      • 3.2.1.2. Growing Research Initiatives
      • 3.2.1.3. Increasing R&D Initiatives
      • 3.2.1.4. Development Of Novel Treatments
      • 3.2.1.5. Increasing Regulatory Approvals
      • 3.2.1.6. Growing Applications of AI
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Drop in Consumption
      • 3.2.2.2. Emerging Drug Resistance
      • 3.2.2.3. Stringent Regulations
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Anti-infectives Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political & Legal landscape
      • 3.3.2.2. Economic and Social landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental landscape
    • 3.3.3. Regulatory Framework by Key Countries
    • 3.3.4. Estimated Animal Population, by Key Species, by Key Countries, 2021 - 2023
    • 3.3.5. Prevalence of Key Infectious Diseases, by key species, (2024)
    • 3.3.6. COVID-19 Impact Analysis

Chapter 4. U.S. Veterinary Anti-infectives Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Anti-infectives Market: Animal Movement Analysis
  • 4.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
  • 4.4. Livestock Animal
    • 4.4.1. Production Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Poultry
      • 4.4.2.1. Poultry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Swine
      • 4.4.3.1. Swine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Cattle
      • 4.4.4.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Sheep & Goats
      • 4.4.5.1. Sheep & Goats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.6. Fish
      • 4.4.6.1. Fish Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Companion Animal
    • 4.5.1. Companion Animal Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Dogs
      • 4.5.2.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Cats
      • 4.5.3.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Veterinary Anti-infectives Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Anti-infectives Market: Product Movement Analysis
  • 5.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 5.4. Antimicrobials
    • 5.4.1. Antimicrobials Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Cephalosporins
      • 5.4.2.1. Cephalosporins Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Tetracyclines
      • 5.4.3.1. Tetracyclines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Penicillin
      • 5.4.4.1. Penicillin Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Macrolides
      • 5.4.5.1. Macrolides Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.6. Others (Quinoles, sulfonamides, polymyxins)
      • 5.4.6.1. Others (Quinoles, sulfonamides, polymyxins) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Antifungals
    • 5.5.1. Antifungals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Antivirals
    • 5.6.1. Antivirals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Veterinary Anti-infectives Market: By Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Anti-infectives Market: By Route of Administration Movement Analysis
  • 6.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by route of administration, 2021 to 2033 (USD Million)
    • 6.3.1. Oral
      • 6.3.1.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Injectables
      • 6.3.2.1. Injectables Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Others
      • 6.3.3.1. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Veterinary Anti-infectives Market: By Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Anti-infectives Market: By Type Movement Analysis
  • 7.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by type, 2021 to 2033 (USD Million)
    • 7.3.1. OTC
      • 7.3.1.1. OTC Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Prescription
      • 7.3.2.1. Prescription Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Anti-infectives Market: By Distribution Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Veterinary Anti-infectives Market: By Distribution Channel Movement Analysis
  • 8.3. U.S. Veterinary Anti-infectives Market Size & Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
    • 8.3.1. Hospital/Clinic Pharmacy
      • 8.3.1.1. Retail Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.2. Retail Pharmacies
      • 8.3.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.3.3. E-commerce
      • 8.3.3.1. E-commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heap Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. Zoetis
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Boehringer Ingelheim
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Merck & Co. Inc.
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Dechra Pharmaceuticals Plc.
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Elanco Animal Health
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Ceva Sante Animale
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Virbac
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Biogenesis Bago
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Vetoquinol
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Calier
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Norbrook Laboratories
      • 9.3.11.1. Participant's Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Product Benchmarking
      • 9.3.11.4. Strategic Initiatives
  • 9.4. Strategy Mapping
    • 9.4.1. Mergers & Acquisitions
    • 9.4.2. Partnerships & Collaborations
    • 9.4.3. Expansion
    • 9.4.4. Product launch
    • 9.4.5. Product Approval
    • 9.4.6. Others
  • 9.5. List of Key Companies
    • 9.5.1. List of Manufacturers
    • 9.5.2. List of Distributors

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Veterinary Anti-infectives Market, By Animal, 2021 - 2033 (USD Million)
  • Table 4 U.S. Veterinary Anti-infectives Market, By Livestock, 2021 - 2033 (USD Million)
  • Table 5 U.S. Veterinary Anti-infectives Market, By Companion Animal, 2021 - 2033 (USD Million)
  • Table 6 U.S. Veterinary Anti-infectives Market, By Product, 2021 - 2033 (USD Million)
  • Table 7 U.S. Veterinary Anti-infectives Market, By Antimicrobial, 2021 - 2033 (USD Million)
  • Table 8 U.S. Veterinary Anti-infectives Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 9 U.S. Veterinary Anti-infectives Market, By Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Veterinary Anti-infectives Market, By Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Veterinary Anti-infectives Market, Market Segmentation
  • Fig. 8 Market Driver Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Regional Marketplace: Key Takeaways
  • Fig. 14 U.S. Veterinary Anti-infectives Market, for Animal, 2021 - 2033 (USD Million)
  • Fig. 15 U.S. Veterinary Anti-infectives Market, for Livestock Animal, 2021 - 2033 (USD Million)
  • Fig. 16 U.S. Veterinary Anti-infectives Market, for Poultry, 2021 - 2033 (USD Million)
  • Fig. 17 U.S. Veterinary Anti-infectives Market, for Swine, 2021 - 2033 (USD Million)
  • Fig. 18 U.S. Veterinary Anti-infectives Market, for Cattle, 2021 - 2033 (USD Million)
  • Fig. 19 U.S. Veterinary Anti-infectives Market, for Sheep & Goats, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. Veterinary Anti-infectives Market, for Fish, 2021 - 2033 (USD Million)
  • Fig. 21 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. Veterinary Anti-infectives Market, for Companion Animal, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. Veterinary Anti-infectives Market, for Dogs, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. Veterinary Anti-infectives Market, for Cats, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. Veterinary Anti-infectives Market, for Product, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. Veterinary Anti-infectives Market, for Antimicrobial, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Veterinary Anti-infectives Market, for Tetracyclines, 2021 - 2033 (USD Million)
  • Fig. 29 U.S. Veterinary Anti-infectives Market, for Penicillin, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. Veterinary Anti-infectives Market, for Cephalosporins, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. Veterinary Anti-infectives Market, for Macrolides, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Veterinary Anti-infectives Market, for Quinolones, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. Veterinary Anti-infectives Market, for Antifungals, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. Veterinary Anti-infectives Market, for Antivirals, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. Veterinary Anti-infectives Market, for Antiparasitic, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Veterinary Anti-infectives Market, for Others, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. Veterinary Anti-infectives Market, for Route of Administration, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. Veterinary Anti-infectives Market, for Oral, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. Veterinary Anti-infectives Market, for Injectable, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Veterinary Anti-infectives Market, for Topical, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. Veterinary Anti-infectives Market, for Type, 2021 - 2033 (USD Million)
  • Fig. 43 U.S. Veterinary Anti-infectives Market, for OTC, 2021 - 2033 (USD Million)
  • Fig. 44 U.S. Veterinary Anti-infectives Market, for Prescription, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. Veterinary Anti-infectives Market, for Distribution Channel, 2021 - 2033 (USD Million)
  • Fig. 46 U.S. Veterinary Anti-infectives Market, for Hospital/ Clinic Pharmacy, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Veterinary Anti-infectives Market, for Retail Pharmacies, 2021 - 2033 (USD Million)